ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)

Rasonque's price signals a sustainability issue for future cancer drugs. Other cancer drugs will likely launch at similar or higher prices, raising long-term questions about affordability and the viability of such pricing models in oncology.
Tap to vote and see what everyone thinks.
Summary by ByteBrief